Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells

Ann Surg. 2014 Apr;259(4):750-9. doi: 10.1097/SLA.0b013e318295c160.

Abstract

Objective: To assess the contribution of hypoxia and bone marrow-derived cells to aggressive outgrowth of micrometastases after liver surgery.

Background: Liver surgery generates a microenvironment that fosters aggressive tumor recurrence. These areas are characterized by chronic hypoxia and influx of bone marrow-derived cells.

Methods: The contribution of hematopoietic cell types was studied in mice lacking specific components of the immune system and in irradiated mice lacking all bone marrow-derived cells. Tumor cells were derived from colorectal cancer patients and from a metastatic tumor cell line. Hypoxia-induced changes in stem cell and differentiation marker expression, clone-forming potential, and metastatic capacity were assessed. The effect of vascular clamping on cancer stem cell (CSC) characteristics was performed in mice bearing patient-derived liver metastases.

Results: Immune cells and bone marrow-derived cells were not required for aggressive outgrowth of micrometastases in livers treated with surgery. Rather, hypoxia was sufficient to promote invasion and accelerate metastatic outgrowth. This was associated with a rapid loss of differentiation markers and increased expression of CSC markers and clone-forming capacity. Likewise, metastases residing in ischemia-reperfusion-injured liver lobes acquired CSC characteristics. Despite their renowned general resistance to chemotherapy, clone-forming CSCs were readily killed by the hypoxia-activated prodrug tirapazamine.

Conclusions: Surgery-generated hypoxia in the liver causes rapid dedifferentiation of tumor cells into immature CSCs with high clone- and metastasis-forming capacity. The results help explain the phenomenon of aggressive local tumor recurrence after liver surgery and offer a potential strategy to kill aggressive CSCs by hypoxia-activated prodrugs.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / metabolism
  • Blotting, Western
  • Catheter Ablation
  • Cell Line, Tumor
  • Colorectal Neoplasms / pathology*
  • Flow Cytometry
  • Hematopoietic Stem Cells / pathology
  • Hepatectomy* / methods
  • Humans
  • Hypoxia / etiology*
  • Hypoxia / metabolism
  • Hypoxia / pathology
  • Immunohistochemistry
  • Liver Neoplasms, Experimental / metabolism
  • Liver Neoplasms, Experimental / pathology
  • Liver Neoplasms, Experimental / secondary*
  • Liver Neoplasms, Experimental / therapy
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred NOD
  • Mice, Nude
  • Mice, SCID
  • Neoplasm Invasiveness / pathology
  • Neoplasm Micrometastasis / pathology
  • Neoplasm Recurrence, Local / metabolism
  • Neoplasm Recurrence, Local / pathology*
  • Neoplasm, Residual / metabolism
  • Neoplasm, Residual / pathology*
  • Neoplastic Stem Cells / metabolism
  • Neoplastic Stem Cells / pathology
  • Phenotype
  • Postoperative Complications* / metabolism
  • Postoperative Complications* / pathology
  • Real-Time Polymerase Chain Reaction
  • Reperfusion Injury / etiology
  • Reperfusion Injury / metabolism
  • Reperfusion Injury / pathology
  • Tirapazamine
  • Triazines / therapeutic use

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Triazines
  • Tirapazamine